1. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas 
Noémie Leblay, MSc, Frédéric Leprêtre, PhD, Nolwenn Le Stang, MSc, Amandine Gautier-Stein, PhD, Laurent Villeneuve, MSc, Sylvie Isaac, MD, Denis Maillet, MD, Françoise Galateau-Sallé, MD, PhD, Céline Villenet, BS, Shéhérazade Sebda, BS, Alexandra Goracci, MD, Graham Byrnes, PhD, James D McKay, PhD, Martin Figeac, PhD, Olivier Glehen, MD, PhD, François-Noël Gilly, MD, PhD, Matthieu Foll, PhD, Lynnette Fernandez-Cuesta, PhD, Marie Brevet, MD, PhD 
Journal of Thoracic Oncology 
Volume 12, Issue 4, Pages (April 2017)
DOI: /j.jtho
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Overview of BAP1 status in malignant peritoneal mesothelioma. (A) Distribution of BRCA1 associated protein 1 gene (BAP1) mutations across the different protein domains. The height of the blue bars correlates with the frequency of the observed mutation. (B) Overview of BAP1 alterations detected in the 46 peritoneal mesotheliomas. Gray means that data are not available. (C) Examples of negative (left panel) and positive (right panel) staining for BRCA1 associated protein 1 (BAP1) nuclear expression in two peritoneal mesotheliomas. HCF1, host cell factor C1; ID, identifier.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Survival analyses. (A) Cox proportional hazards regression for BRCA1 associated protein 1 (BAP1) nuclear expression and histological type. (B) Cox proportional hazards regression for BRCA1 associated protein 1 gene (BAP1) mutation and histological type. (C) Cox proportional hazards regression for BAP1 nuclear expression and/or BAP1 mutation and histological type. EMM, epithelial malignant mesothelioma; MM, malignant mesothelioma; CI95%, 95% confidence limit; HR, hazard ratio.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions